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Abstract 
Insulin secretion from pancreatic β-cells plays a central role in the control of blood glucose 
levels. The amount of insulin released by β-cells is precisely adjusted to match the organism 
requirements. A number of conditions occurring during life, including pregnancy and obesity, 
can result in a decrease in the sensitivity of insulin target tissues and in the consequent rise in 
the insulin needs. To preserve glucose homeostasis, the augmented insulin demand requires a 
compensatory expansion of the mass of pancreatic β-cells and an increase in their secretory 
activity. This compensatory process is known to be accompanied by modifications in β-cell 
gene expression but the molecular mechanisms underlying this phenomenon are still poorly 
understood. Emerging evidence indicate that at least part of these compensatory events may 
be orchestrated by changes in the level of a novel class of gene regulators, the microRNAs. 
Indeed, several of these small non-coding RNAs have either positive or negative impacts on 
β-cell proliferation and survival. The studies reviewed in this paper suggest that the balance 
between the actions of these two groups of microRNAs with opposing functional effects 
determines whether β-cells expand sufficiently to maintain blood glucose levels in the normal 
range or fail to meet the insulin demand with a consequent progression toward diabetes 
manifestation. A better understanding of the mechanisms governing the changes in the 
microRNA profile will open the way for the development of new strategies to prevent and/or 
treat type 2 and gestational diabetes. 
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Introduction 
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by a 
diminished sensitivity of insulin target tissues, including liver, skeletal muscles and adipose 
tissue, and the inability of the pancreatic β-cells to secrete enough insulin to sustain the 
organism demand. In pre-diabetic conditions, β-cells compensate the insulin resistant state of 
the target tissues by increasing their number and size and by augmenting the amount of 
hormone released in response to glucose and fatty acids [1]. The duration of this 
compensatory state differs between individuals and can eventually last for the entire life. 
When β-cells can no longer face the elevated insulin demand, they become dysfunctional and 
their survival is impaired favoring the development of T2DM. Despite intensive efforts, the 
precise mechanisms underlying compensatory β-cell mass expansion are still not well 
understood. Changes in the functional β-cell mass are known to necessitate adaptations in 
gene expression programs but the key factors driving this phenomenon are still not fully 
elucidated. 
In the last few years, microRNAs (miRNAs) have been discovered to form a complex 
regulatory network governing the activities of β-cells. These small non-coding RNA 
molecules act as transcriptional repressors by binding to the 3’UTR of target mRNAs (Figure 
1) [2]. The current estimations indicate that the human genome encodes for more than 1800 
miRNA precursors producing up to 2585 mature miRNAs [3]. Notably, a single miRNA can 
bind more than hundred different target mRNAs, hence modulating directly or indirectly the 
expression of numerous genes. Indeed, at least 60% of the protein-coding genes are believed 
to be under the control of miRNAs [4]. In view of this, miRNAs are now recognized as major 
regulators of gene expression and key players in the control of several biological and 
pathological processes, including diabetes mellitus [5]. The potential role of miRNAs in the 
development of diabetes and its complications has been reviewed extensively in the past 
years [6-10]. Here, we will focus specifically on the contribution of miRNAs to the control of 
the functional β-cell mass.  
 
Evidence for the involvement of miRNAs in the control of pancreatic β-cell mass and 
function 
The potential role of miRNAs in β-cell differentiation and in the control of β-cell 
function was initially investigated by knocking-down Dicer1, the enzyme required for the 
maturation of most miRNAs (see Figure 1). Whole-body deletion of Dicer1 in mice results in 
early embryonic lethality [11] but, surprisingly, Dicer1-hypomorphic mice, expressing about 
20% of wild type Dicer1 level, are viable and display histologically normal tissue 
development throughout fetal and neonatal stages. However, starting from 4 weeks of age, 
the pancreas showed morphologic abnormalities [12]. Lynn and colleagues generated a 
pancreatic Dicer1-null mice who survived until birth but died at 3 days of age (P3) [13]. 
These Pdx1-Cre Dicer1 animals displayed severe defects in pancreas development and in the 
differentiation of the endocrine lineage, with strong impairment in β-cell formation. In 
another study, deletion of Dicer1 specifically in pancreatic endocrine progenitor cells did not 
affect specialization of hormone-expressing cells during embryogenesis but displayed loss of 
hormone expression during neonatal phase. [14]. Moreover, during the neonatal period these 
Ngn3-Cre Dicer mice exhibited altered islet organization, reduced β-cell mass and decreased 
proinsulin mRNA expression with a consequent reduction in insulin content. As expected, 
these mice developed hyperglycemia and overt diabetes within 2 weeks of age [14].   
To investigate more precisely the role of miRNAs in insulin-secreting cells, Dicer1 
was conditionally deleted using Cre recombinase system under control of the promoter of the 
rat insulin 1 (RIP1) or 2 (RIP2) gene. Of note, rodents have 2 nonallelic insulin genes as 
opposed to human that have a single copy of the insulin gene. Both RIP1 and RIP2 are 
commonly used to delete a gene specifically in beta-cells. Kalis et al. generated a β-cell 
specific deletion of Dicer1 [15] under the regulation of RIP1. Fetal and neonatal β-cell 
development was not affected but RIP1-Cre Dicer1 null mice became progressively 
hyperglycemic, leading to diabetes onset in adulthood. These animals display defects in islet 
number, size and architecture, in β-cell mass and in insulin biosynthesis and secretion. Two 
other research groups developed conditioned Dicer1 deletion under the regulation of RIP2. 
Lynn and colleagues did not observed any morphological defect in pancreatic islets of 8 
month-old mice [13]. In opposite, Mandelbaum and colleagues observed reduced beta-cell 
number and mass and insulin content in pancreatic islets of 4 month-old mice [16]. Moreover, 
these RIP2-Cre Dicer1 null mice were glucose intolerant at the age of 1-2 month and the 
same trend was also observed at the age of 8-10 months. Of note, mutant mice exhibited 
mosaic islets, meaning that not all beta-cells underwent Cre recombination leading to a mix 
of “mutant” (Cre-positive cells in which Dicer1 activity was disrupted) and wild-type (Cre-
negative) beta-cells. Interestingly, in early post-natal life, most of the beta-cells were knocked 
down for Dicer1 but a gradual loss of mutant beta-cells was than observed. By the age of 
P30, almost no Cre-positive cells could be detected. Therefore, the proliferation of Cre-
negative cells progressively compensated for the reduction of beta-cell mass [16]. Finally, 
Melkman-Zehavi et al. engendered tamoxifen-inducible RIP-Cre Dicer1 mice to explore the 
involvement of miRNAs in adult β-cell function [17]. Tamoxifen-treated animals developed 
hyperglycemia in both fasted and fed states and insulin intolerance few weeks after the 
injections. Interestingly, the 50% decrease in Dicer1 measured in pancreatic islets of 
Tamoxifen-treated mice correlated with a reduction of the level of several miRNAs and with 
a marked decline in insulin gene expression, leading to reduced insulin content and impaired 
glucose-induced insulin secretion. As expected, the β-cell mass was not affected by the loss 
of Dicer1 in adult mice [17]. Taken together, these studies underline the key role of Dicer1, 
and its associated miRNA network, in endocrine pancreas development, β-cell differentiation, 
preservation of the β-cell mass and proper function of insulin-secreting cells.  
In adult mice, similar results were obtained when Ago2 expression was deregulated. 
Ago2 is the most abundant member of the argonaute protein family in β-cells and is the 
catalytic component of the RNA-induced silencing complex (RISC) complex necessary for 
miRNA action (see Figure 1). Mice overexpressing Ago2 in β-cells showed normal body 
weight and plasmatic concentration of glucose and insulin [18]. However, when challenged 
with glucose, mice overexpressing Ago2 exhibited an impaired insulin secretion leading to 
transient elevation in glycaemia. Morphometric analysis revealed an increase in β-cell 
number, mass and proliferative capacity. In contrast, knockdown of Ago2 in β-cells resulted 
in the reduction in the number, mass and proliferative capacity of β-cell and in a lower insulin 
content [18]. Islet architecture was not affected and no changes in cell-death were detected. 
Loss of Ago2 resulted in enhanced insulin secretion in response to glucose, leading to 
improved glucose tolerance. Of note, Ago1 expression was increased in pancreatic islets of 
Ago2 knockout mice, suggesting a partial compensatory mechanism. Taken together, these 
results indicate that an appropriate level of Ago2 is necessary to maintain an appropriate 
functional β-cell mass.  
 
Role of specific miRNAs in the development of β-cells and in the control of their 
activities  
 The involvement in β-cell development and function of particular miRNAs highly 
expressed in pancreatic islets such as let-7, miR-7 and miR-375, was explored in detail both 
in vitro and in vivo. Let-7 was the first miRNA discovered in C. elegans [19]. Mammalian 
cells are known to contain a family of closely related let-7 miRNAs sharing a common seed 
region. Let-7 family members are involved in cell differentiation and have been associated to 
the development of several forms of cancer [20]. Members of the let-7 family are highly 
expressed in pancreatic islets [21, 22] but their precise role in regulating the activity of 
insulin-secreting cells is still not completely understood. Transgenic mice overexpressing let-
7a/d/f or let-7g in all tissues have reduced body size and weight, decreased fat mass and 
impaired glucose homeostasis mainly due to a decrease in insulin release by the endocrine 
pancreas in response to glucose [23, 24]. Interestingly, overexpression of let-7a/d/f solely in 
β-cells led also to impaired glucose tolerance, but not when let-7 expression was selectively 
increased either in muscle, adipose tissue, neurons, or adipocytes, suggesting a preponderant 
role of β-cells in this metabolic phenotype. In contrast, global knockdown of let-7 using anti-
miR oligonucleotides improved glucose homeostasis and was sufficient to prevent impaired 
glucose intolerance induced by high-fat feeding, but this was mainly the result of improved 
insulin sensitivity of target tissues [23]. Looking in more details at the mechanisms in liver 
and muscles, let-7 was found to regulate the expression of the insulin receptor and of insulin 
receptor substrate 2 (IRS2) [23] and to affect the insulin-PI3K-mTOR axis [24]. The mode of 
action of let-7 in β-cells remains to be investigated. 
Mir-375 was first cloned from an insulin-secreting cell line and was found to be 
highly enriched in the endocrine pancreas [25]. In their pioneering work, Poy et al. 
demonstrated that blockade of miR-375 expression in vitro results in enhanced glucose-
induced insulin secretion whereas the overexpression of this non-coding RNA reduces insulin 
release in response to different secretagogues. This effect was at least in part attributed to 
silencing of myotrophin, one of the direct targets of miR-375 [25]. In addition to its negative 
effect on insulin exocytosis, overexpression of miR-375 was reported to inhibit insulin gene 
expression in response to glucose by down-regulating PDK1 and thus inhibiting the 
phosphoinositol-3-kinase (PI3K) pathway [26]. The expression of miR-375 was found to be 
under the control of two transcription factors playing a pivotal role in islet cell differentiation, 
namely NeuroD1 and Pdx1 [27]. Indeed, in vivo studies revealed that miR-375 is involved in 
the development of the endocrine pancreas [28, 29]. Deletion of miR-375 in mice resulted in 
a reduction in the β-cell mass and in an increase in the α-cell number, leading to disrupted 
islet architecture [29]. In line with these observations, KO-miR375 mice exhibited 
hyperglycemia and elevated plasma glucagon levels. In contrast, plasma insulin levels and 
glucose-induced insulin secretion were unaffected. When these animals were crossed with 
leptin deficient ob/ob mice, they developed severe diabetes due to the incapacity of β-cells to 
expand and compensate for obesity-associated insulin resistance [29]. The α-cell number was 
also increased in islets of KO-miR375-ob/ob compared to WT-ob/ob mice. Taken together, 
these results point to a key role for miR-375 in regulating islet cell development and β-cell 
mass expansion. A direct causative link between miR-375 dysregulation and diabetes 
development remains however to be settled. In fact, an increase in the level of pre-miR-375 
has been reported in GK rats [26] but this observation was not confirmed by an independent 
study [30]. A small elevation of miR-375 was also reported in islets of ob/ob and DIO mice 
[18, 29], but changes in miR-375 expression were neither detected in other studies by 
microarray profiling of islets of ob/ob, db/db and DIO mice [31, 32] nor in islets of T2DM 
human donors [21, 33]. Interestingly, increased levels of miR-375 were observed in the islets 
of the offspring of rats fed a low-protein diet during pregnancy. The level of miR-375 
remained elevated until the adulthood, suggesting that deregulation of this miRNA 
contributes to defective endocrine pancreas activity and to the increased risk of developing 
T2DM typically observed upon in utero malnutrition [34]. 
As explained above, miR-375 plays complex regulatory roles in pancreatic islets 
being involved not only in the control of β-cell mass expansion and insulin secretion but 
governing also the activity and proliferation of glucagon-secreting α-cells that have opposing 
effects on blood glucose levels. All studies carried out so far searched for changes in the 
expression of miR-375 in whole islets. However, changes in the balance between the levels of 
miR-375 in α- and β-cells will probably have more relevant impacts on the metabolic control. 
Detailed analysis of miR-375 expression in FACS-sorted α- and β-cells isolated from 
diabetes animal models or from T2DM human donors will help addressing this issue. 
In human and mouse, miR-7 is highly enriched in the developing endocrine pancreas 
and in the islets of Langerhans in adults [35-37]. Down-regulation of miR-7 in mice embryos 
using small oligonucleotides called morpholinos resulted in a decrease in β-cell number and 
in reduced insulin production, leading to post-natal glucose intolerance [38]. Interestingly, the 
expression of miR-7 is regulated by the endocrine-specific transcription factors NeuroD/beta2 
and Ngn3  [37]. Three different pre-miR-7 precursors (miR-7a1, miR-7a2 and miR-7b) are 
co-expressed in mammalian pancreatic islets and generate two mature miR-7 isoforms (miR-
7a and miR-7b) sharing the same seed sequence. Of the three precursors, miR-7a2 is the most 
abundant in mice islets [39]. In fact, deletion of pre-miR-7a1 decreased the level of mature 
miR-7 by only 20% whereas deletion of pre-miR-7a2 reduced the expression by 80%. RIP-
Cre-miR-7a2 mice exhibited improved glucose tolerance mainly resulting from enhanced 
insulin release. No differences in islet architecture and β-cell mass were observed in KO-
miR7 mice compared to wild type mice. Augmentation of insulin secretion in response to 
secretagogues was also detected ex vivo in islets isolated from 5 and 35 weeks old KO-miR7 
mice. In agreement with these findings, several genes involved in late stages of insulin 
granule fusion, such as SNCA, were identified as direct targets of miR-7. In the same study, 
deregulation of miR-7 expression in vivo did not impact on cell survival and β-cell 
proliferation [39]. However, another group reported that blockade of miR-7a in adult mouse 
islet cells activates the mTOR pathway and promotes β-cell proliferation [40]. Thus, changes 
in the level of miR-7 can modulate the activities of β-cells and deregulation of its expression 
can potentially affect the adaptive capacity of β-cells, contributing to the development of 
diabetes. The expression of miR-7 was reported to be decreased by about half in mice fed a 
high fat diet, in ob/ob mice and in young db/db mice [21, 39] but to be increased in islets of 
older diabetic db/db mice [39]. In obese and T2DM human donors, expression of miR-7 was 
found down-regulated [21]. Other studies reported no significant differences in miR-7 levels 
upon global miRNA profiling of islets isolated from these and other animal models or from 
T2DM donors [18, 30-32]. The level of this miRNA seems to vary over the different stages of 
the disease with an initial decrease in response to insulin resistance followed by an increase 
during the decompensation phase. Thus, according to the time point selected, changes in 
miR-7 level may possibly have escaped detection. 
Interestingly, a novel class of non-coding RNAs, the circular RNAs, was recently 
described [41]. One of them, ciRS-7 that is highly expressed in nervous tissues is suggested 
to modulate the availability of miR-7 since its sequence contains more than 60 conserved 
binding sites for this specific miRNA [42, 43]. Therefore, the expression of miR-7 seems to 
be tightly regulated and measurement of ciRS-7 would be of interest in β-cells under 
physiological and physiopathologial conditions.  
 
Contribution of other miRNAs to compensatory β-cell mass expansion or to β-cell 
failure 
Beside let-7, miR-7 and miR-375, several other miRNAs have been investigated in 
vitro or ex vivo in β-cells for their involvement in the regulation of insulin biosynthesis and 
secretion, proliferation and apoptosis/survival. Here, we will focus exclusively on miRNAs 
that display expression changes in diabetes animal models or in the islets of T2DM donors. 
For a more exhaustive list of miRNAs potentially affecting the activities of β-cells we refer 
the reader to other recent reviews in the field [6-9]. 
To identify miRNAs potentially contributing to compensatory β-cell mass expansion 
or, on the contrary, to β-cell dysfunction associated with the manifestation of T2DM, several 
studies analyzed the miRNA expression profiles in well-characterized diabetes animal 
models. The Goto-kakizaki (GK) rat is a model of non-obese, insulin resistant and 
moderately hyperglycaemic animals that spontaneously develop T2DM early in life. 
Pancreatic islets of GK rats exhibit defective insulin release in response to glucose [44]. 
Esguerra et al. performed a global miRNA profiling of islets of 8 weeks old GK rats and 
identified 30 miRNAs differentially expressed compared to Wistar control rats [30]. The 
changes of several upregulated (miR-124, -130a, -132, -142-3p, -142-5p -212, -335, -376a, -
409-3p and -433) or down-regulated (miR-708) miRNAs were then confirmed by qPCR. The 
expression of four of these miRNAs (miR-130a, miR-132, miR-212 and miR-335) were 
found to be regulated by hyperglycemia. Computational predictions revealed that the putative 
target of the upregulated miRNAs are enriched for genes involved in the secretory process 
and were suggested to contribute to the defective insulin secretion observed in GK rats [30]. 
However, the functional impact of the increase in the level of these miRNA was not 
experimentally assessed in this study.  
 To understand the influence of the genetic background and obesity on miRNA 
regulation, Zhao et al. quantified by microarray the expression of these non-coding RNAs in 
pancreatic islets of diabetes-resistant B6 mice and diabetes-susceptible BTBR mice and 
compared their expression profiles to their morbidly obese counterpart, the B6-ob/ob and the 
BTBR-ob/ob mice, respectively [32]. Obesity affected miRNA expression profiles in both B6 
and BTBR strains. Among the observed changes, miR-27b, miR-184, miR-203, miR-210, 
miR-338-3p and miR-383 were found to be down-regulated in both B6-ob/ob and BTBR-
ob/ob mice compared to their respective lean controls, whereas miR-34a, miR-34b, miR-132, 
miR-152, miR-199a and miR-212 were upregulated. Interestingly, some of the miRNA 
changes were observed in only one strain, such as miR-204 and miR-7b that were modified in 
response to obesity in BTBR but not in B6 mice. The magnitude of deregulation was also 
different between the two strains. For example, miR-132 and miR-212 were increased more 
than 14 times in B6 mice and only 3 times in BTBR mice. Therefore, the genetic background 
seems to influence the changes in miRNA expression observed in response to obesity. A 
better understanding of the roles of these miRNAs in the regulation of β-cell function and 
survival may help understanding the causes underlying resistance (B6) and susceptibility 
(BTBR) to diabetes. 
 Nesca et al. used two models of T2DM to assess whether miRNA deregulation can 
contribute to β-cell adaptation to insulin resistance and to β-cell dysfunction associated with 
the manifestation of the disease [31]. The global miRNA profile of pancreatic islets was 
investigated in pre-diabetic and diabetic db/db mice and in diet-induced obesity (DIO) mice. 
Compared to the respective controls, more than 60 miRNAs were found to be differentially 
expressed in these two obesity-associated animal models of T2DM. As expected, most of the 
changes detected in these two models were consistent with those reported in ob/ob mice [32]. 
Interestingly, miR-132 displayed a striking increase and miR-184, miR-203, miR-210 and 
miR-338-3p a strong down-regulation already in young (6 weeks old) db/db mice that are 
obese and insulin-resistant but still normoglycemic. The reduction of miR-184 and miR-210 
was further decreased in older, overtly diabetic, db/db mice while the level of miR-132, miR-
203 and miR-338-3p remained approximately constant between pre-diabetic and diabetic 
animals. The expression of many other miRNAs was only altered in diabetic db/db mice. For 
example, miR-21, miR-34a, miR-146, miR-199a-3p and -5p and miR-802 were increased 
whereas the level of miR-383 declined [31]. The increase of miR-802 in pancreatic islets as 
well as in several other tissues of db/db mice including liver and white adipocytes was also 
reported by Kornfeld et al. [45]. Db/db mice are severely obese and diabetic while DIO mice 
are moderately overweight after being fed on high-fat diet for 8 weeks and are in a pre-
diabetic state (insulin resistant, hyperglycemic and hyperinsulinemic). However, global 
miRNA profiling of pancreatic islets of these two models led to partially overlapping changes 
in miRNA expression.  
The functional roles of several of these miRNAs were investigated in details by 
mimicking the up- or the down-regulation observed in db/db mice and/or DIO mice in 
dispersed rat and human islet cells [31]. The alteration of the level of miR-21, miR-34a, miR-
146a, miR-199a-3p, miR-203, miR-210 and miR-383 were found to increase the fraction of 
cells undergoing apoptosis [31, 46]. Moreover, the overexpression of some of these miRNAs 
was found to perturb insulin secretion. The changes in the level of these miRNAs occur only 
in diabetic or glucose-intolerant animals suggesting that they contribute to β-cell dysfunction 
associated with T2DM. So far the specific role of miR-802 in β-cells has not been 
investigated. However, transgenic mice overexpressing miR-802 developed glucose 
intolerance and insulin resistance, suggesting the involvement of this miRNA in the 
regulation of glucose homeostasis in vivo [45]. The expression of miR-802 is particularly 
elevated in hepatocytes where it regulates insulin sensitivity by targeting Hfn1b. This 
transcription factor plays a role also in β-cells and mutations in the Hfn1b gene can cause the 
development of a rare form of Maturity Onset Diabetes of the Young (MODY5). Thus, an 
increase in the expression of miR-802 may potentially contribute also to failure of β-cells 
under insulin-resistant conditions.  
Another group of miRNAs, including miR-204 and miR-200 family members, has 
been shown to be induced by the Thioredoxin-interacting protein (TXNIP), a cellular redox 
regulator that is up-regulated in diabetes and triggers β-cell apoptosis [47, 48]. The induction 
of miR-204 triggered by TXNIP was found to reduce MafA expression and to cause an 
impairment in insulin biosynthesis [48]. In contrast, miR-200 overexpression promotes β-cell 
apoptosis and inhibits epithelial-mesenchymal transition, a process thought to be involved in 
compensatory β-cell mass expansion [47].  
In contrast to the miRNAs described above, miR-132, miR-184 and miR-338-3p have 
their expression already modified during the compensatory phase and have a positive impact 
of β-cell activities. Increase in the level of miR-132 favored cell survival under pro-apoptotic 
conditions such as prolonged exposure to elevated concentrations of cytokines or free fatty 
acids [31]. Moreover, overexpression of miR-132 amplified the amount of insulin secreted in 
response to glucose without affecting insulin content and promoted β-cell proliferation in 
dispersed rat islet cells. The beneficial effect of miR-132 on insulin release has been 
suggested to be mediated by direct down-regulation of carnitine acyl-carnitine translocase 
(CACT), a mitochondrial protein important for β-oxidation [49].  
Down-regulation of miR-184 also increased β-cell proliferation [31]. The role of miR-
184 in the control of β-cell functions was investigated in vivo by Tattikota et al [18]. This 
independent study confirmed the decrease in the expression of miR-184 in ob/ob, db/db and 
DIO mice and demonstrated also a reduction of the level of this non-coding RNA in islets of 
T2DM human donors. Interestingly, constitutive miR-184 deletion in mice resulted in a 
reduction of blood glucose levels in fasted state combined with increased plasma insulin 
concentrations. In response to a glucose challenge, KO-miR184 mice displayed improved 
glucose tolerance and transiently elevated insulin release without any difference in insulin 
sensitivity in target tissues. Moreover, analysis of pancreatic sections of these mice revealed 
an increase in β-cell number and mass and an augmentation of the β-cell proliferative rate. As 
computationally predicted, Ago2 was confirmed to be a direct target of miR-184 and its 
expression was inversely correlated with the level of the miRNA in islets of human donors. 
To investigate the role of miR-184 and Ago2 in the compensatory phase preceding the 
manifestation of T2DM, transgenic miR-184 were crossed with ob/ob mice, resulting in 
sustained expression of miR-184 (as opposed to the diminution of miR-184 observed in WT 
ob/ob mice) and a decrease in Ago2 expression without affecting the level of abundant islet 
miRNAs such as miR-375. Transgenic miR-184 ob/ob mice exhibited more pronounced 
hyperglycemia and reduced circulating insulin levels compared to WT ob/ob mice due to the 
incapacity of these animals to compensate the insulin resistant state with an increase in the β-
cell mass. Pancreatic insulin content was also blunted in these transgenic ob/ob animals. Of 
note, α-cell mass was not affected by the overexpression of miR-184. These results suggest 
that the reduction of miR-184 observed in pancreatic islets of pre-diabetic and diabetic rodent 
models and of human T2DM donors is part of the mechanism enabling the β-cells to 
compensate for the insulin-resistant state of target tissues.  
 Another miRNA displaying expression changes during the β-cell compensatory phase 
of db/db mice and DIO mice is miR-338-3p. Interestingly, the level of this non-coding RNA 
is decreased not only in these diabetes models but also during pregnancy, another condition 
characterized by compensatory β-cell mass expansion [50]. Down-regulation of miR-338-3p 
in dispersed rat islet cells favored β-cell proliferation without affecting insulin content and 
secretion and protected both rat and human islet cells against cytokine- and fatty acid-induced 
apoptosis [50]. The direct targets of miR-338-3p mediating this effect were not identified. 
However, the beneficial effects of miR-338-3p down-regulation in β-cells correlated with a 
reduction in the expression of pro-apoptotic Bad and an elevation of genes playing key roles 
in β-cell survival and proliferation such as Bcl2, Birc5, Foxm1, CyclinD1, Igf1 and Irs2. 
Looking at the signaling mechanisms regulating the expression of miR-338-3p revealed that 
the level of this miRNA is controlled by hormones capable of activating the cAMP-
dependent pathway such as the incretin GLP-1 and, via its unconventional receptor GPR30, 
estrogen. Indeed, the induction of β-cell proliferation by GLP1 was blunted by 
overexpressing miR-338-3p, suggesting that the beneficial effect of GLP1 on β-cell mass is 
achieved, at least in part, by reducing miR-338-3p.  
 
miRNA changes in islets of human T2DM donors 
A limited number of studies have been carried out to detect deregulation in miRNA profiles 
in human pancreatic islets of T2DM individuals. In non-diabetic donors, a positive 
association was observed between miR-122, miR-127-3p, miR-184 and miR-375 expression 
and the level of insulin mRNA, and a negative correlation was detected between miR-127-3p 
and miR-184 and the amount of insulin released in response to glucose. However, these 
associations were absent in glucose intolerant donors [51]. In the same study, miR-21 was 
found to be significantly upregulated and miR-127-3p and miR-375 had a tendency to be 
more elevated in islets of glucose intolerant donors [51]. In other independent studies, 
expression of miR-375 was found to be increased in total pancreas [52] but not in isolated 
pancreatic islets of T2DM donors [33]. Two other miRNAs, miR-187 and miR-124a, were 
found to be upregulated in islets of individuals suffering from T2DM, whereas miR-7 and 
miR-184 were down-regulated [18, 33, 39, 53]. Overexpression of both miR-187 and miR-
124a was linked in in vitro rodent models to a reduction in glucose-induced insulin secretion 
by directly targeting HIPK3 or Rab27A, Mtpn and Foxa2, respectively [33, 53-55]. As 
already mentioned above, the role of miR-7 and miR-184 were investigated in details in 
rodent animal models [18, 39].  
A recently published study led to the identification of several miRNAs differentially 
expressed in islets from T2DM versus non-diabetic donors [21]. The expression of, miR-369, 
miR-487a, miR-655 and miR-656 were diminished whereas miR-7, miR-187, miR-187*, 
miR-224 and miR-589 were augmented in T2DM donors. Interestingly many of the miRNAs 
deregulated in T2DM donors belong to a cluster that is generated from the maternally 
imprinted locus DLK1-MEG3. MEG3 and 8 miRNA members of this cluster displayed 
reduced levels in islets of diabetic patients. Moreover, the miRNAs of DLK1-MEG3 cluster 
had, on average, a 16-fold higher expression in human FACS-sorted β-cells compared to α-
cells. RNA level of MEG3 was also found to be highly enriched in β-cells. Interestingly, β-
cell-specific expression of this miRNA cluster could be attributed to the methylation status of 
the MEG3 promoter, which was impaired in islets from T2DM donors. Finally, IAPP and 
TP53INP1 were identified as direct targets of this miRNA cluster and an elevation in the 
expression of these genes was suggested to contribute to β-cell death observed in T2DM. 
Taken together, this elegant study suggest that epigenetic modifications resulting in the 
reduction of the level of the DLK1-MEG3 miRNA cluster can lead to β-cell dysfunction and 
can predispose the individual to the development of T2DM. 
Studies in human islets are obviously highly relevant for the understanding of the 
causes of T2DM and for identifying new strategies to cure this metabolic disease. As 
discussed in detail elsewhere [56], human islet studies provide precious information that 
cannot be obtained with animal models but are subjected to major limitations. In fact, human 
islets can only be obtained from cadaveric donors, drastically limiting the amount of material 
available for these experiments. Consequently, in most studies the cohorts are relatively 
small, inevitably leading to results variability and difficulties in matching control and diabetic 
donors for confounding factors such as body mass index (BMI), age, gender and ethnicity. 
Moreover, the interpretation of human islet data can be influenced by the duration of the 
disease, the medications used to control the glycaemia and possible differences in the α/β cell 
ratio occurring in T2DM patients [57, 58]. Because of all these limitations, the use of animal 
models is indispensable to precisely understand the molecular mechanisms underlying the 
manifestation of the disease and will be required also in the future to complement the studies 
carried out with human islets.  
 
Conclusion and perspectives 
miRNAs are now recognized as important regulators of β-cell survival, proliferation and 
function. Hence, it was not surprising to find changes in their expression under conditions 
associated with modifications in the functional β-cell mass. A closer look at the results 
obtained by independent investigators, reveals that the miRNAs displaying expression 
changes can be subdivided in two groups displaying opposing functional effects (Figure 2). 
Under conditions of insulin resistance, the expression of several miRNAs including miR-7, 
miR-132, miR-184 and miR-338-3p and possibly miR-375 is modified in order to promote 
compensatory β-cell mass expansion and amplification of insulin secretion [18, 31, 49, 50]. 
On the other hand, deregulation of the DLK1-MEG3 miRNA cluster and of miR-34, miR-
124a, miR-146, miR-187, miR-199a-5p, miR-203, miR-210 and miR-383 have a detrimental 
impact on β-cell survival and function and can predispose to the development of T2DM [21, 
31, 33, 53]. An appropriate balance between the level of the miRNAs with a positive and a 
negative impact on proliferation and survival of β-cells is essential to compensate for the rise 
in the insulin needs under conditions of pregnancy and obesity and to maintain blood glucose 
homeostasis. In fact, excessive expression of miRNAs with a deleterious impact on β-cell 
proliferation will promote progression toward glucose intolerance and T2DM onset. On the 
other side, unbalanced expression of miRNAs triggering compensatory β-cell mass expansion 
may also be inappropriate. In fact, many of these miRNAs are oncomiRs and are deregulated 
in several forms of cancers [59]. Thus, in the absence of a counteracting effect, these 
miRNAs can potentially trigger uncontrolled proliferation of insulin-secreting cells and favor 
the development of insulinomas. A precise understanding of the functional interplay between 
these two groups of miRNAs expressed in β-cells will be essential for the design of new 
therapeutic approaches to prevent and treat different forms of diabetes.  
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Figure legends 
 
Figure 1: The canonical miRNA biogenesis pathway. 1- miRNAs are transcribed by the 
RNA polymerase II as primary molecules (pri-miRNAs) containing characteristic stem-loop 
structures. 2- Pri-miRNAs are recognized by the microprocessor complex composed of 
DGCR8/Pasha proteins and cleaved by the RNase III-type enzyme Drosha to produce 
hairpin-structured precursors of 70 nucleotides (pre-miRNAs). 3- Thereafter, miRNAs 
precursors are transported to the cytoplasm by Exportin-5 and 4- further cleaved by the 
endoribonuclease Dicer to generate an imperfect miRNA/miRNA* duplex of around 22 
nucleotides. 5- Mature miRNA strands in association with members of the Argonaute family 
are incorporated into the RNA-induced silencing complex (RISC). 6- Finally, the RISC 
complex guided by the mature miRNA binds to miRNA recognition element within the 
3’untranslated region (3’UTR) of the target mRNA, leading to translational inhibition and/or 
transcript degradation.  
 
Figure 2: Deregulation of particular miRNAs during the development of T2DM. In 
healthy non-diabetic state, pancreatic beta-cells secrete insulin in response to the organism 
demand. However, in genetically susceptible individuals that face environmental factors like 
overnutrition, inactivity and ageing, beta-cells need to compensate to overcome the insulin 
resistant state of the target tissues. Augmentation of miR-132 and reduction of miR-7, miR-
184 and miR-338-3p levels have been suggested to be part of mechanisms leading to increase 
beta-cell mass and function. Appropriate amount of miR-375 is also required for proper 
adaptation of beta-cells to insulin resistant state. T2DM develops when beta-cells are unable 
anymore to face the organism need in insulin. Downregulation of the miRNA cluster DLK1-
MEG3 and miR-203, miR-210, miR-383 as well as upregulation of miR-34a, miR-124a, 
miR-146, miR-187 and miR-199a favor beta-cell dysfunction and death associated with onset 
of diabetes. 
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